The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Updates on HBI0101, a CAR T-cell therapy, for R/R multiple myeloma
Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discussed advancements in anti-BCMA CAR T-cell therapy for relapsed/refractory (R/R) multiple myeloma (MM), emphasizing its efficacy and the challenges of high cost, limited availability, and lengthy waiting periods. Dr Lebel has worked with his team to develop a novel anti-BCMA CAR-T therapy, HBI0101 (NXC-201), and here he presents some safety and efficacy data from a Phase I clinical trial testing this product. Despite a high proportion of the study population being frail, a 92% response rate was observed. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
